BioNexus Gene Valuation
| BGLC Stock | USD 5.10 1.53 23.08% |
At this time, the firm appears to be undervalued. BioNexus Gene Lab shows a prevailing Real Value of $6.25 per share. The current price of the firm is $5.1. Our model approximates the value of BioNexus Gene Lab from analyzing the firm fundamentals such as Profit Margin of (0.23) %, return on equity of -0.25, and Current Valuation of 5.77 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that BioNexus Gene's price fluctuation is abnormally volatile at this time. Calculation of the real value of BioNexus Gene Lab is based on 3 months time horizon. Increasing BioNexus Gene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioNexus Gene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNexus Stock. However, BioNexus Gene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.1 | Real 6.25 | Hype 6.14 | Naive 3.65 |
The real value of BioNexus Stock, also known as its intrinsic value, is the underlying worth of BioNexus Gene Lab Company, which is reflected in its stock price. It is based on BioNexus Gene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioNexus Gene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioNexus Gene Lab helps investors to forecast how BioNexus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNexus Gene more accurately as focusing exclusively on BioNexus Gene's fundamentals will not take into account other important factors: BioNexus Gene Total Value Analysis
BioNexus Gene Lab is currently expected to have valuation of 5.77 M with market capitalization of 9.16 M, debt of 210.56 K, and cash on hands of 1.34 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BioNexus Gene fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.77 M | 9.16 M | 210.56 K | 1.34 M |
BioNexus Gene Investor Information
About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNexus Gene Lab has Price/Earnings (P/E) ratio of 350.0. The entity recorded a loss per share of 1.19. The firm had not issued any dividends in recent years. BioNexus Gene had 1:10 split on the 7th of April 2025. Based on the measurements of operating efficiency obtained from BioNexus Gene's historical financial statements, BioNexus Gene Lab is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.BioNexus Gene Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioNexus Gene has an asset utilization ratio of 91.15 percent. This indicates that the Company is making $0.91 for each dollar of assets. An increasing asset utilization means that BioNexus Gene Lab is more efficient with each dollar of assets it utilizes for everyday operations.BioNexus Gene Ownership Allocation
BioNexus Gene Lab retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.BioNexus Gene Profitability Analysis
The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.27 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioNexus Gene's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioNexus Gene and how it compares across the competition.
About BioNexus Gene Valuation
The stock valuation mechanism determines BioNexus Gene's current worth on a weekly basis. Our valuation model uses a comparative analysis of BioNexus Gene. We calculate exposure to BioNexus Gene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioNexus Gene's related companies.BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people.
BioNexus Gene Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.8 M | |
| Quarterly Earnings Growth Y O Y | -0.95 |
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |